Shares in Insmed have rocketed after the biotech reported positive results in a highly-anticipated clinical trial of brensocatib in the respiratory disorder bronchiectasis
Following the launch of LifeArc’s £100 million programme, Chronic Respiratory Infection Translational Challenge (CRI TC) – for the acceleration of the development of new clinical solutions
US biotech Insmed has trumpeted updated phase 2 data from its brensocatib, at this week’s virtual European Respiratory Society conference, showing the drug prolonged time to exacerbations c
Cancer Research UK has provided £5.9 million ($7.7 million) in funding to a project that will explore the use of artificial intelligence in trials of radiotherapy treatments as well as virt